|
Volumn 14, Issue 4, 2008, Pages 226-229
|
Characteristics of and trends in the late-stage biopharmaceutical pipeline
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTISENSE OLIGONUCLEOTIDE;
MONOCLONAL ANTIBODY;
PEPTIDE;
POLYCLONAL ANTIBODY;
RECOMBINANT PROTEIN;
VACCINE;
BLOOD DISEASE;
CLINICAL TRIAL;
CROHN DISEASE;
DATA BASE;
DECISION MAKING;
DRUG INDUSTRY;
DRUG MANUFACTURE;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE COST;
HEALTH CARE PERSONNEL;
HUMAN;
IMMUNOPATHOLOGY;
INFECTION;
INSULIN DEPENDENT DIABETES MELLITUS;
MEDICAL SPECIALIST;
MULTIPLE SCLEROSIS;
NEOPLASM;
PRIORITY JOURNAL;
PSORIASIS;
REVIEW;
RHEUMATOID ARTHRITIS;
TELEPHONE;
TREATMENT INDICATION;
ULCERATIVE COLITIS;
UNITED STATES;
BIOPHARMACEUTICS;
CLINICAL TRIALS, PHASE II AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG APPROVAL;
DRUGS, INVESTIGATIONAL;
HUMANS;
UNITED STATES;
|
EID: 41849112386
PISSN: 10880224
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (11)
|
References (8)
|